Concert Pharmaceuticals Stock News

Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones.

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

The company is changing hands in a deal worth at least $576 million.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and

Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price S

The average of price targets set by Wall Street analysts indicates a potential upside of 126.6% in Concert (CNCE). While the effectiveness of this highly sought-after metric is questionable, the posit

Concert (CNCE) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh

Does Concert Pharmaceuticals (CNCE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price S

Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022.

Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a